Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.56 |
| ▸ | ANPEP | P15144 | 9/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7727313 | 0.89 | BTK (0.46) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL22506037 | 0.89 | BTK (0.49) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL7727315 | 0.89 | BTK (0.46) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL7731684 | 0.89 | BTK (0.46) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL854269 | 0.88 | BTK (0.45) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL30422379 | 0.85 | BTK (0.43) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL13938227 | 0.81 | MMP2 (0.47) | MMP2ANPEPALDH1A1 | |
| SCHEMBL13938226 | 0.81 | MMP2 (0.47) | MMP2ANPEPALDH1A1 | |
| SCHEMBL10085244 | 0.80 | BTK (0.38) | MMP2ANPEPBTKCTSKCA1 | |
| SCHEMBL7722111 | 0.80 | BTK (0.38) | MMP2ANPEPBTKCTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MMP2 999/4885ANPEP 1703/4885BTK 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.